Merged from 2 sources — review for redundancy.
A pregnancy-specific syndrome characterized by new-onset hypertension (≥140/90 mmHg) and end-organ dysfunction (proteinuria ≥300 mg/24h or other organ damage) after 20 weeks gestation, arising from failed maternal immune tolerance to paternal antigens. From a cPNI perspective, preeclampsia represents a catastrophic failure of the Th2 shift and T regulatory cells expansion that should occur in healthy pregnancy, resulting in Th1/Th17-dominated inflammation, shallow placental invasion, endothelial dysfunction, and systemic vascular pathology. This is a textbook example of how inadequate immunological priming—specifically insufficient exposure to seminal fluid and paternal antigens before conception—creates evolutionary mismatch between ancestral reproductive patterns and modern contraceptive practices.
Imagine pregnancy as a delicate treaty negotiation between two armies: the mother's immune system (the "home defense force") and the fetus (carrying half its DNA from the father—a genetic "foreigner"). For the treaty to work, the mother's immune system must recognize the father's genetic signature as "friendly" and deploy peacekeeping forces (T regulatory cells, IL-10, TGF-beta) instead of attack troops (Th1, Th17, inflammatory cytokines).
Now here's the critical part: this treaty requires advance diplomatic contact. In ancestral conditions, couples would have months or years of regular sexual contact before conception—each exposure to seminal fluid is like a diplomatic briefing, training the mother's immune system (especially dendritic cells in the vaginal and uterine mucosa) to recognize and tolerate the father's antigens. semen contains TGF-beta, IL-10, and Prostaglandins—literal immunosuppressive "white flag" molecules that say "we come in peace."
But if a woman uses barrier contraception (condoms) for years or has limited sexual contact before conception, her immune system never gets these briefings. When pregnancy occurs, the fetus—carrying the father's "foreign" antigens—lands in hostile territory. The mother's immune system sees it as an invasion and launches a full Th1/Th17 attack. The placenta can't invade deeply into the uterine wall (because immune cells are blocking it), spiral arteries don't remodel properly, the placenta becomes hypoxic, and desperate placental cells start releasing "distress flares"—anti-angiogenic factors like sFlt-1 and soluble endoglin—into the mother's bloodstream. These toxins damage blood vessels throughout her body: kidneys (proteinuria), brain (seizures in eclampsia), liver (HELLP syndrome), and vasculature (hypertension). Preeclampsia is what happens when the peacekeeping briefings never occurred, and war breaks out instead of alliance.
Preeclampsia develops through a two-stage pathophysiological cascade:
Stage 1: Failed Placentation (Weeks 8-20)
-
Inadequate immune priming: Insufficient exposure to paternal antigens in seminal fluid before conception prevents:
- dendritic cells conditioning to paternal MHC antigens
- T regulatory cells (CD4+CD25+FoxP3+) expansion—normally Tregs should increase 2-3 fold by second trimester
- Th2 cytokine dominance (IL-4, IL-10, IL-13)—instead, Th1/Th17 responses persist
-
Immunological attack on trophoblast:
- Excessive Th1 cytokines (IFN-γ, TNF-α, IL-12) → activated macrophages and NK cells at implantation site
- Th17 cells produce IL-17 → recruit neutrophils → tissue damage
- Inadequate IL-10 and TGF-beta → failed suppression of inflammatory cascades
- Result: shallow trophoblast invasion (normally extravillous trophoblasts invade to 1/3 of myometrial depth; in preeclampsia they stop at decidua)
-
Failed spiral artery remodeling:
- Normal pregnancy: trophoblasts invade spiral arteries, replace endothelium, degrade smooth muscle → high-flow, low-resistance vessels
- Preeclampsia: immune attack prevents deep invasion → arteries remain narrow, muscular, vasoactive
- Result: placental hypoperfusion and Oxidative Stress
Stage 2: Maternal Syndrome (After Week 20)
-
Placental ischemia and oxidative stress:
- Hypoxic placenta → HIF-1 activation
- Increased reactive oxygen species (ROS) production
- Mitochondrial dysfunction in trophoblasts
- Release of syncytiotrophoblast microparticles into maternal circulation
-
Anti-angiogenic factor release:
- sFlt-1 (soluble VEGF receptor-1) binds and neutralizes VEGF and placental growth factor (PlGF)
- Soluble endoglin antagonizes TGF-beta signaling
- sFlt-1/PlGF ratio >85 at <34 weeks is diagnostic for preeclampsia
- These factors cause widespread maternal endothelial dysfunction
-
Systemic inflammation and coagulation:
- TNF-α, IL-6, IL-8 elevation → systemic inflammatory state
- Endothelial activation → increased vascular permeability
- Upregulation of adhesion molecules (VCAM-1, E-selectin)
- Platelet activation → microthrombi formation
- Nitric Oxide (NO) production ↓ → vasoconstriction
-
Clinical manifestations:
- Hypertension (vasoconstriction + endothelial dysfunction)
- Proteinuria (glomerular endotheliosis—swollen glomerular endothelial cells)
- Cerebral edema → headaches, visual disturbances, seizures (eclampsia)
- Hepatic dysfunction → elevated liver enzymes, subcapsular hematoma
- HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets)
graph TD
A[Insufficient paternal antigen exposure] --> B[Failed Treg expansion]
A --> C[Inadequate Th2 shift]
B --> D[Excessive Th1/Th17 response]
C --> D
D --> E[NK cell & macrophage activation]
E --> F[Trophoblast invasion blocked]
F --> G[Shallow placentation]
G --> H[Spiral artery remodeling failure]
H --> I[Placental hypoperfusion]
I --> J["HIF-1α activation"]
J --> K[Oxidative stress]
K --> L[sFlt-1 & sEng release]
L --> M["VEGF & TGF-β antagonism"]
M --> N[Systemic endothelial dysfunction]
N --> O[Hypertension]
N --> P[Proteinuria]
N --> Q[Multi-organ damage]
D --> R["TNF-α, IL-6, IL-17 release"]
R --> N
Preeclampsia is a profound illustration of evolutionary mismatch in reproductive medicine. In hunter-gatherer populations with long-term pair bonding and no barrier contraception, preeclampsia rates are extremely low (0.5-1%). Modern prevalence of 2-8% reflects:
-
Barrier contraception: Condom use for years prevents seminal fluid exposure → no immune priming. Women who conceive after prolonged condom use have 2-3 fold higher preeclampsia risk.
-
New partner effect: Even multiparous women have elevated risk with a new partner (insufficient exposure to this partner's antigens). Risk resets with new paternal genetics.
-
Short cohabitation time: Modern couples who conceive quickly (<6 months sexual activity) lack adequate immune conditioning. Evolutionarily mismatched from ancestral 2-3 years of sexual activity before first conception.
Clinical Assessment Must Include:
- Sexual history: duration of relationship before conception, contraceptive methods used, frequency of unprotected intercourse
- Partner change history (new partner = reset immune tolerance)
- Donor gamete use (egg/sperm donation = zero prior antigen exposure = high risk)
- Autoimmune conditions (systemic lupus erythematosus, autoimmune diseases—already dysregulated immune tolerance)
Intervention Implications:
- Preconception counseling: For women planning pregnancy, recommend transition from barrier contraception to non-barrier methods (IUD, hormonal) 6-12 months before conception attempts while maintaining regular sexual activity with intended father
- Seminal fluid exposure: Regular vaginal or oral exposure to partner's semen promotes immune tolerance via mucosal dendritic cells → Treg induction
- Low-dose aspirin: 81-150 mg daily from 12 weeks onward in high-risk women → improves placental perfusion via COX-1 inhibition (↓ thromboxane, preserves prostacyclin)
- Calcium supplementation: 1-2g daily in low-calcium populations → reduces preeclampsia risk by 50%
- Vitamin D: Adequate levels (>30 ng/mL) support Treg function and immune tolerance
- Anti-inflammatory diet: Omega-3 (EPA/DHA) promote resolvins and Prostaglandins series 3 → immune resolution
- Stress reduction: Chronic stress → cortisol resistance → failed Th2 shift (see Cortisol resistance)
Biomarkers for Monitoring:
- sFlt-1/PlGF ratio (>85 indicates placental dysfunction)
- IL-6, TNF-α (elevated in preeclampsia vs normal pregnancy)
- Treg percentage (should be 10-15% of CD4+ cells in healthy pregnancy; <8% in preeclampsia)
- Blood pressure, urine protein, platelet count (standard clinical)
This represents a clear example where the selfish immune system prioritizes maternal survival over fetal tolerance when immunological "safety signals" are absent—evolutionary logic that becomes pathological in modern contraceptive contexts.
- Affects 2-8% of pregnancies globally; <1% in hunter-gatherer populations (evolutionary baseline)
- 10-15% of maternal deaths worldwide; leading cause of maternal/fetal morbidity in developed nations
- Risk highest in first pregnancy with any partner (primigravida: 5-7%)
- Prolonged sexual activity (>12 months) with same partner reduces risk by 50-70%
- Barrier contraception (condoms) increases risk 2-3 fold by preventing seminal fluid exposure
- New partner increases risk even in multiparous women (odds ratio 1.9)
- Donor egg/sperm pregnancies have 3-4 fold higher risk (complete antigen novelty)
- Oral sex provides protective effect via buccal/sublingual antigen exposure and IL-10-inducing tolerogenic dendritic cells
- seminal fluid contains: TGF-beta (10-50 ng/mL), IL-10 (100-500 pg/mL), PGE2, immunosuppressive peptides (HLA-G)
- sFlt-1/PlGF ratio >85 (before 34 weeks) or >110 (after 34 weeks) confirms diagnosis
- T regulatory cells should expand from 5-7% of CD4+ cells (non-pregnant) to 10-15% by second trimester; in preeclampsia remain <8%
- Th1/Th2 ratio inverted: normal pregnancy Th2-dominant (ratio ~0.5); preeclampsia Th1-dominant (ratio >2.0)
- Early-onset preeclampsia (<34 weeks) has stronger immune pathology component; late-onset (>34 weeks) more vascular/metabolic
- Low-dose aspirin started at 12-16 weeks reduces risk by 10-15% in high-risk women
- Delivery is the only cure—removes placental source of anti-angiogenic factors
- immune tolerance — preeclampsia is fundamentally a failure of maternal immune tolerance to semi-allogeneic fetus carrying paternal antigens
- Pregnancy — preeclampsia is pregnancy-specific disorder emerging from immune-endocrine-vascular interface unique to gestation
- paternal antigens — insufficient exposure to paternal HLA molecules prevents dendritic cells conditioning and T regulatory cells expansion
- Th1 — excessive Th1 response (IFN-γ, TNF-α, IL-12) characterizes preeclampsia immunology and blocks trophoblast invasion
- Th2 — failure to establish Th2 cytokine dominance (IL-4, IL-10, IL-13) prevents immune tolerance required for pregnancy
- Th17 — elevated Th17 responses (IL-17, IL-23) contribute to neutrophil recruitment and placental inflammation
- T regulatory cells — inadequate Treg expansion (<8% of CD4+ vs 10-15% normal) fails to suppress maternal immune attack on fetus
- sexual activity — regular unprotected sexual activity is primary mechanism of immune priming to paternal antigens via seminal fluid
- semen — seminal fluid is immunological "conditioning agent" containing TGF-beta, IL-10, Prostaglandins, HLA-G that induce tolerance
- TGF-beta — seminal TGF-β (10-50 ng/mL per ejaculate) programs dendritic cells toward tolerogenic phenotype and promotes Treg differentiation
- IL-10 — anti-inflammatory cytokine in seminal fluid and required for maternal tolerance; inadequate IL-10 in preeclampsia
- Prostaglandins — seminal PGE2 promotes Treg induction and suppresses Th1 responses; preeclampsia has prostaglandin imbalance
- dendritic cells — seminal factors condition vaginal/uterine DCs to capture paternal antigens and present to T cells in tolerogenic context
- endothelial dysfunction — systemic consequence of placental anti-angiogenic factors (sFlt-1, soluble endoglin) causing widespread vascular damage
- hypertension — defining clinical feature resulting from vasoconstriction (Nitric Oxide deficiency) and endothelial permeability
- inflammation — preeclampsia characterized by systemic inflammatory state with elevated IL-6, TNF-α, CRP similar to autoimmune disease
- autoimmune diseases — preeclampsia shares mechanisms with autoimmunity (immune attack on "self+foreign," failed tolerance, Th1/Th17 dominance)
- fertility — sexual activity patterns affect both conception success and preeclampsia risk through immune priming mechanisms
- barrier contraception — condom use increases preeclampsia risk by preventing antigen exposure; evolutionary mismatch between modern practice and ancestral reproduction
- NK cells — uterine natural killer cells (CD56bright) crucial for spiral artery remodeling; dysregulated NK activation in preeclampsia attacks trophoblasts
- VEGF — vascular endothelial growth factor neutralized by sFlt-1 in preeclampsia, causing endothelial dysfunction and anti-angiogenic state
- Oxidative Stress — placental hypoxia generates reactive oxygen species contributing to endothelial damage and systemic inflammation
- HIF-1 — hypoxia-inducible factor activated in ischemic placenta drives anti-angiogenic factor production
- Nitric Oxide — reduced NO bioavailability in preeclampsia contributes to vasoconstriction and hypertension
- cortisol resistance — chronic stress-induced glucocorticoid resistance may prevent Th2 shift necessary for pregnancy tolerance
- Chronic stress — psychosocial stress increases preeclampsia risk via immune dysregulation and failed Th2 dominance
- evolutionary mismatch — preeclampsia exemplifies mismatch between ancestral reproductive patterns (long sexual cohabitation) and modern practices (barrier contraception, short partner exposure)
- placental insufficiency — shallow trophoblast invasion and failed spiral artery remodeling result in chronic placental underperfusion
- Vitamin D — vitamin D promotes Treg function and immune tolerance; deficiency (<20 ng/mL) associated with higher preeclampsia risk
- Omega-3 — EPA/DHA support anti-inflammatory resolvins and protectins; low omega-3 status associated with preeclampsia
- Module 1 — immune tolerance failure, seminal fluid immunology, evolutionary mismatch in reproduction
- Module 2 — stress-immunity-endocrine integration, pregnancy as immune challenge, oral dysbiosis-pregnancy complications link
A pregnancy-specific syndrome characterized by new-onset hypertension (≥140/90 mmHg) after 20 weeks gestation with proteinuria (≥300 mg/24h) or end-organ dysfunction. It represents a catastrophic failure of maternal-fetal immune tolerance and placental vascular remodeling, driven by systemic inflammation, anti-angiogenic signaling, and endothelial dysfunction. Preeclampsia affects 3-8% of pregnancies globally and carries significant maternal and fetal morbidity and mortality risk.
Think of pregnancy as a foreign embassy being built on home soil. The mother's immune system is like a border patrol that must learn to tolerate the half-foreign fetus (carrying paternal antigens). In a healthy pregnancy, the father's sperm acts like diplomatic envoys—repeated exposure through seminal fluid and sexual activity before conception trains the mother's immune guards (T regulatory cells) to recognize paternal antigens as friendly. The placenta then remodels the mother's spiral arteries like construction crews widening roads—removing the muscular walls and opening the vessels wide to deliver high blood flow to the growing embassy.
In preeclampsia, this diplomatic training never happened properly (nulliparity, barrier contraception, limited paternal antigen exposure). When the placenta tries to remodel the arteries, the immune system treats it like an invasion. The Th1 and Th17 attack squads mobilize instead of standing down. The placenta becomes ischemic—like a city under siege with blocked supply routes. In desperation, it releases anti-angiogenic distress signals (sFlt-1, soluble endoglin) that flood the mother's bloodstream. These signals block VEGF—the "open the blood vessels" molecule—everywhere, not just in the placenta. Blood vessels throughout the mother's body constrict and leak. The result: hypertension (narrowed vessels), proteinuria (leaky kidney filters), liver dysfunction (damaged hepatic endothelium), and seizures (cerebral edema). The only cure is eviction—deliver the placenta and end the siege.
Early Pathogenesis: Failed Immune Tolerance and Trophoblast Invasion
-
Inadequate Paternal Antigen Priming (pre-conception):
- Insufficient exposure to paternal antigens in seminal fluid → inadequate T regulatory cells (Tregs) expansion
- Seminal TGF-β normally induces Treg differentiation via TGF-beta signaling
- Barrier contraception or limited sexual exposure prevents proper immune priming
-
Defective Spiral Artery Remodeling (6-18 weeks gestation):
- Trophoblast invasion normally replaces spiral artery endothelium and smooth muscle with fibrinoid material
- Requires MMP-2, MMP-9 secretion by extravillous trophoblasts
- In preeclampsia: shallow invasion → spiral arteries retain muscular walls → high-resistance, low-flow placental perfusion
-
Placental Ischemia and Oxidative Stress:
- Inadequate blood flow → placental hypoxia → stabilization of HIF-1 (hypoxia-inducible factor-1α)
- HIF-1α → upregulation of sFlt-1 (soluble Fms-like tyrosine kinase-1) and soluble endoglin (sEng)
- Placental Oxidative Stress → release of Reactive Oxygen Species, lipid peroxides, HMGB1 (danger signal)
Anti-Angiogenic State
-
sFlt-1 and Soluble Endoglin Release:
- sFlt-1 acts as decoy receptor → binds and neutralizes VEGF and PlGF (placental growth factor)
- Soluble endoglin binds TGF-β1 → prevents endothelial TGF-beta signaling
- sFlt-1/PlGF ratio >85 (late preeclampsia) or >110 (early preeclampsia) diagnostic threshold
- Loss of VEGF signaling → endothelial Nitric Oxide production ↓ → vasoconstriction
-
Systemic Endothelial Dysfunction:
- VEGF blockade → endothelial eNOS activity ↓ → NO production ↓
- Increased endothelin-1 (potent vasoconstrictor)
- Loss of endothelial glycocalyx → increased vascular permeability
- Activation of NLRP3 inflammasome in endothelial cells
Immune Dysregulation
-
Th1/Th17 Dominance Over Treg:
- Th17 cells expansion → IL-17 production → neutrophil recruitment and vascular inflammation
- IL-6 and TNF-α elevation (typically >10 pg/mL IL-6 in severe cases)
- Inadequate T regulatory cells function → loss of immune tolerance
- IFN-γ from Th1 cells → macrophage activation → more inflammatory cytokines
-
Complement Activation:
- Alternative complement pathway activation on placental tissue
- C5a and C5b-9 (membrane attack complex) deposition on trophoblasts
- Complement activation → neutrophil recruitment and oxidative burst
-
Neutrophil Activation and NETosis:
- Circulating neutrophils primed by IL-8, IL-6
- NETosis → release of DNA-histone complexes and proteases
- NETs damage endothelium directly and activate coagulation cascade
Multi-Organ Manifestations
-
Renal Dysfunction (glomerular endotheliosis):
- Loss of fenestrated endothelium in glomerular capillaries
- Podocyte damage → proteinuria (>300 mg/24h)
- Reduced GFR, elevated Creatine and uric acid
-
Hepatic Dysfunction:
- Periportal hemorrhage and hepatocyte necrosis
- Elevated transaminases (AST/ALT), subcapsular hematoma (HELLP syndrome)
-
CNS Effects:
- Cerebral edema, posterior reversible encephalopathy syndrome (PRES)
- Seizures (eclampsia) from hypertensive encephalopathy and endothelial leak
graph TD
A[Inadequate Paternal Antigen Exposure] --> B[Insufficient Treg Expansion]
B --> C[Defective Trophoblast Invasion]
C --> D[Shallow Spiral Artery Remodeling]
D --> E[Placental Ischemia & Hypoxia]
E --> F["HIF-1α Stabilization"]
F --> G[sFlt-1 & sEng Release]
E --> H[ROS & Oxidative Stress]
G --> I[VEGF/PlGF Sequestration]
I --> J[Endothelial Dysfunction]
J --> K[Decreased NO Production]
K --> L[Vasoconstriction]
B --> M[Th1/Th17 Dominance]
M --> N["IL-6, TNF-α, IL-17 ↑"]
N --> O[Systemic Inflammation]
O --> J
J --> P[Glomerular Endotheliosis]
J --> Q[Hepatic Dysfunction]
J --> R[Cerebral Edema]
P --> S[Proteinuria & Hypertension]
Q --> S
R --> T[Eclampsia]
Immune Tolerance Failure and Evolutionary Mismatch
Preeclampsia exemplifies the importance of immune tolerance in pregnancy and reveals how modern reproductive patterns create evolutionary mismatch. Historically, women had prolonged sexual relationships before conception, ensuring adequate paternal antigen exposure. Today, barrier contraception, limited sexual partners before conception, and use of donor sperm all reduce this critical immune priming. The condition highlights the selfish immune system concept—the maternal immune system prioritizes self-protection over fetal tolerance when inadequately conditioned.
Risk Factor Stratification
High-risk patients include:
- Nulliparous women (2-3× risk) due to lack of prior immune adaptation
- Obesity (BMI >30): chronic low-grade inflammation primes excessive inflammatory response, adipocyte-derived Leptin shifts Th1/Th17 balance
- Pre-existing autoimmune disease: baseline immune dysregulation
- Type 2 Diabetes/insulin resistance: endothelial dysfunction at baseline, AGE accumulation
- Previous preeclampsia: 15-20% recurrence risk
- Chronic hypertension, Chronic Kidney Disease
- Short interval between partners or use of barrier contraception throughout relationship
Biomarker Monitoring
- sFlt-1/PlGF ratio: >85 (late-onset), >110 (early-onset) predicts preeclampsia within 1-4 weeks; <38 rules out within 1 week (negative predictive value >99%)
- Blood pressure: ≥140/90 mmHg on two occasions ≥4 hours apart
- Proteinuria: ≥300 mg/24h or protein:creatinine ratio ≥0.3
- Platelets: <100,000/μL (HELLP syndrome)
- Liver enzymes: AST/ALT >2× upper limit normal
- Uric acid: >5.5 mg/dL often precedes clinical diagnosis
Prevention Strategies (cPNI Approach)
-
Pre-conception Immune Priming:
- Encourage consistent unprotected sexual activity (non-barrier methods) for 3-6 months pre-conception with intended father
- Oral sex may enhance oral tolerance to paternal antigens (mucosa-associated lymphoid tissue exposure)
-
Omega-3 Supplementation:
- EPA+DHA 1-2g/day starting pre-conception or first trimester
- Mechanisms: Resolvins and Protectins production → inflammation resolution, reduced Th17 activation
- Meta-analysis shows 15-20% risk reduction
-
Anti-inflammatory Nutrition:
-
Low-Dose Aspirin:
-
Address Metabolic Dysfunction:
-
Stress Reduction and Vagal Tone:
Long-Term Consequences
Women with preeclampsia have 3-4× increased lifetime risk of:
- Cardiovascular disease (endothelial dysfunction persists)
- Stroke (cerebrovascular remodeling)
- Chronic kidney disease (glomerular scarring)
- Early-onset dementia (vascular contributions)
This necessitates lifelong cardiovascular risk monitoring and aggressive primary prevention.
- Affects 3-8% of pregnancies globally; higher in nulliparous women (7-10%)
- Diagnostic criteria: BP ≥140/90 mmHg after 20 weeks + proteinuria ≥300 mg/24h OR end-organ dysfunction
- sFlt-1/PlGF ratio >85 (late-onset) or >110 (early-onset) highly predictive
- Risk factors: nulliparity (2-3× risk), obesity (BMI >30), previous preeclampsia (15-20% recurrence), autoimmune disease, chronic hypertension, diabetes, advanced maternal age (>40)
- Only definitive cure is delivery of placenta—symptoms typically resolve within 48-72 hours postpartum
- HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) occurs in 10-20% of severe preeclampsia cases
- Omega-3 supplementation (1-2g EPA+DHA daily) reduces risk by 15-20%
- Low-dose aspirin (81-150 mg/day) from 12-16 weeks reduces risk by ~15% in high-risk women
- Eclampsia (seizures) occurs in 1-2% of preeclamptic women in developed countries
- Preeclampsia increases maternal long-term CVD risk 3-4× and doubles stroke risk
- Maternal immune priming requires 3-6 months regular sexual exposure to paternal antigens for optimal Treg expansion
- Barrier contraception or infrequent intercourse pre-conception significantly increases preeclampsia risk
- Pregnancy — preeclampsia is pregnancy-specific syndrome emerging after 20 weeks gestation
- immune tolerance — fundamental failure of maternal tolerance to paternal antigens drives pathogenesis
- T regulatory cells — inadequate Treg expansion and function central to disease mechanism
- Th17 cells — excessive Th17 responses and IL-17 production contribute to vascular inflammation
- Th1 — inappropriate Th1 activation against fetal antigens instead of Th2 dominance
- endothelial dysfunction — central pathophysiological feature affecting all organ systems
- VEGF — antagonized by sFlt-1, loss of VEGF signaling drives endothelial dysfunction and vasoconstriction
- HIF-1 — stabilized by placental hypoxia, drives sFlt-1 and soluble endoglin production
- Nitric Oxide — production decreased by VEGF blockade, contributing to vasoconstriction
- Oxidative Stress — placental ischemia generates ROS, HMGB1, lipid peroxides
- systemic inflammation — elevated IL-6, TNF-α, IL-17 drive multi-organ pathology
- chronic low-grade inflammation — pre-existing metaflammation in obesity increases susceptibility
- obesity — major risk factor through adipokine dysregulation and baseline inflammation
- insulin resistance — often co-exists and worsens endothelial function
- Type 2 Diabetes — pre-existing diabetes 2-4× increases risk through vascular damage
- omega-3 fatty acids — EPA/DHA supplementation reduces risk via resolvin/protectin production
- Resolvins — specialized pro-resolving mediators from omega-3s promote inflammation resolution
- Aspirin-triggered resolvins — low-dose aspirin shifts to resolvin production
- NLRP3 inflammasome — activated in placental and endothelial cells, amplifies inflammation
- NETosis — neutrophil extracellular trap formation damages endothelium
- Complement — alternative pathway activation on trophoblasts, C5a/C5b-9 deposition
- autoimmune disease — pre-existing autoimmunity increases risk through baseline immune dysregulation
- TGF-beta — seminal TGF-β normally induces Treg expansion; soluble endoglin blocks TGF-β signaling
- IL-6 — elevated >10 pg/mL in severe preeclampsia, shifts Th17 balance
- paternal antigens — inadequate exposure pre-conception prevents immune priming
- Leptin — elevated in obesity, promotes Th1/Th17 shift
- C-reactive protein — elevated as acute phase reactant, marker of systemic inflammation
- Vagus nerve — vagal tone optimization may improve Treg function via cholinergic anti-inflammatory pathway
- Chronic Kidney Disease — long-term consequence of glomerular endotheliosis
- cardiovascular disease — 3-4× increased lifetime risk post-preeclampsia